VfA Cardiac Devices for Dual-Chamber Tachyarrhythmia Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing single chamber implantable medical devices may not fully address cardiac conduction diseases or abnormalities, such as AV dyssynchrony or tachycardia, in all patients, and dual chamber devices with transvenous leads can be cumbersome.
Innovation Solution
The development of ventricle-from-atrium (VfA) devices with tissue-piercing electrodes implanted in the left ventricular myocardium and right atrial electrodes, capable of sensing and delivering cardiac therapy to both atria and ventricles, along with a controller to determine tachyarrhythmias based on atrial and ventricular event rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If dual chamber devices with transvenous leads are used, then comprehensive cardiac conduction management is achieved, but device complexity and invasiveness increase
Solution Approach 1:
The patent extracts the essential sensing and therapy delivery function from the complex transvenous lead system and concentrates it into a single intracardiac device positioned in the right atrium. The tissue-piercing electrode extends through the atrial wall to reach the ventricle, eliminating the need for separate transvenous leads while maintaining dual-chamber capability.
Solution Approach 2:
The intracardiac device performs multiple functions: it senses both atrial and ventricular electrical activity, delivers pacing therapy to both chambers, and detects tachyarrhythmias. This multi-functional design consolidates what previously required separate transvenous leads into a single device.
2Device complexity
If single chamber devices are used, then device simplicity is maintained, but comprehensive treatment of cardiac conduction abnormalities is limited
Solution Approach 1:
The patent transitions from a single-chamber device to a dual-chamber device by extending a tissue-piercing electrode through the atrial wall into the ventricle. This spatial extension across chamber boundaries enables simultaneous sensing and therapy delivery to both atrium and ventricle while maintaining a single intracardiac implant site.
3Adaptability or versatility
If transvenous leads are used, then dual chamber sensing and therapy are achieved, but invasive procedures and surgical complexity increase
Solution Approach 1:
The patent removes the transvenous lead components from the system and replaces them with a single intracardiac device that achieves dual-chamber functionality through a tissue-piercing electrode. This extraction of the lead system simplifies the implantation procedure while maintaining clinical effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Improves the specificity of tachyarrhythmia detection and treatment by providing dual-chamber sensing and therapy, enhancing cardiac rhythm management and reducing the need for transvenous leads.
Implementation Method 1
The electrical impulse is conducted from the AV node to the ventricular myocardium via the bundle of His, bundle branches, and Purkinje fibers
Implementation Method 2
The therapeutic electrical stimulation may be delivered to the heart in the form of pulses or shocks for pacing, cardioversion, or defibrillation
Data Source
AI summary
Ventricle-from-atrium (VfA) devices, systems, and methods may be configured to detect a tachyarrhythmia. For in-stance, an atrial event rate may be compared to a ventricular rate to determine whether a patient's heart is undergoing a tachyarrhythmia. Further, it may be determined whether the tachyarrhythmia is a supraventricular tachycardia or ventricular tachycardia prior to delivering therapy to treat the tachyarrhythmia.